Eur J Neurol 2002 May;9(3):221-226
Toncev G, Milicic B, Toncev S, Samardzic G.
Center of Neurology, Clinical Hospital Center Kragujevac, Svetozara Markovica, Kragujevac, Yugoslavia, Institute for Medical Informatics and Statistics, Svetozara Markovica, Kragujevac, Yugoslavia, Clinical of Surgery, Clinical Hospital Center Kragujevac, Svetozara Markovica, Kragujevac, Yugoslavia, Laboratory of Immunology, School of Medicine, University of Kragujevac, Svetozara Markovica, Kragujevac, Yugoslavia.
Several findings suggest lower levels of serum uric acid in multiple sclerosis (MS) patients
The aim of this study is to investigate relationships of uric acid serum levels in relapse-remitting (RR) MS patients with clinical activity of disease and blood-brain barrier (BBB) condition
Sixty-three definite RRMS patients and 40 controls divided into two groups: 20 healthy donors and 20 patients with other inflammatory neurological diseases (OINDs) were analysed
By using a quantitative enzymatic assay according to the manufacture's protocol and a commercial uric acid standard solution, serum uric acid levels were measured and the results were standardized
To investigate BBB function, magnetic resonance imaging after administration of gadolinium was used
MS patients were found to have significantly lower serum uric acid levels (193.89 +/- 49.05 &mgr;mol/l; mean value +/-SD) in comparison with healthy donors (292.7 +/- 58.65 &mgr;mol/l; P=0.000) and OIND patients (242.7 +/- 46.66 &mgr;mol/l; P=0.001)
We found that MS patients with relapse had significantly lower serum uric acid levels (161.49 +/- 23.61 &mgr;mol/l) than MS patients with remission (234.39 +/- 41.96 &mgr;mol/l; P=0.000) and more over, MS patients with BBB disruption had significantly lower serum uric acid levels (163.95 +/- 26.07 &mgr;mol/l) than those with normal BBB (252.48 +/- 25.94 &mgr;mol/l; P=0.000)
Further, we also found that serum uric acid level independently correlated with disease activity, BBB disruption, and gender
These results indicate that lower uric acid levels in MS patients are associated with relapse and suggest that uric acid might be beneficial in the treatment of MS.